Myelodysplastic Syndromes Clinical Trial
— ELEMENT-MDSOfficial title:
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD): The "ELEMENT-MDS" Trial
The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
Status | Recruiting |
Enrollment | 360 |
Est. completion date | March 11, 2030 |
Est. primary completion date | June 25, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria - Participant has documented diagnosis of MDS according to World Health Organization (WHO) 2016 that meet IPSS-R classification of very low, low, or intermediate-risk disease, (intermediate-risk of = 3.5 IPSS-R score) confirmed via bone marrow aspirate and:. i) < 5% blasts in bone marrow and < 1% blasts in peripheral blood. - Participant is not transfusion dependent (NTD) based on IWG2018 criteria. - Participant has never received treatment with an erythropoiesis stimulating agent (ESA). - Participant has a baseline endogenous serum erythropoietin (sEPO) level of = 500 U/L. - Participant has symptoms of anemia:. i) Participant records a severity score of "moderate" or greater on at least 1 PGI-S item of fatigue, weakness, shortness of breath, or dizziness performed during the screening period. - Participant has a mean baseline Hb concentration prior to randomization of = 9.5 g/dL. Mean Hb is defined as the mean of all central/ local/ pretransfusion available Hb measurements during the 16 weeks prior to randomization (with a minimum of 2 measurements at least 1 week apart). Only Hb levels > 21 days following a transfusion are acceptable. The last measurement must be within 35 days of randomization. Exclusion Criteria - Participant with secondary MDS (that is, MDS that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation for other diseases). - Participant with known history of diagnosis of AML. - Participant with history of cerebrovascular accident (including ischemic, embolic, and hemorrhagic cerebrovascular accident), transient ischemic attack, deep venous thrombosis (including proximal and distal), pulmonary or arterial embolism, arterial thrombosis, or other venous thrombosis within 6 months prior to randomization. - Participant with a history of pure red cell aplasia and/or antibody against erythropoietin. - Other protocol-defined Inclusion/Exclusion criteria apply. |
Country | Name | City | State |
---|---|---|---|
Argentina | Centro Mdico "Barrio Parque" | Buenos Aires | |
Argentina | Local Institution - 0012 | Buenos Aires | |
Argentina | Local Institution - 0009 | Ciudad Autónoma de Buenos Aires | |
Australia | Blacktown Hospital | Blacktown | New South Wales |
Australia | Royal Prince Alfred Hospital | Camperdown | New South Wales |
Australia | Monash Health | Clayton | Victoria |
Australia | Local Institution - 0254 | Coffs Harbour | New South Wales |
Australia | Local Institution - 0246 | Gold Coast | Queensland |
Australia | Austin Health | Heidelberg | Victoria |
Brazil | Hospital Universitario Walter Cantidio | Fortaleza | Ceará |
Brazil | Hospital São Lucas da PUCRS | Porto Alegre | Rio Grande Do Sul |
Brazil | HEMORIO | Rio de Janeiro | |
Brazil | Hospital das Clinicas FMUSP | São Paulo | |
Canada | Tom Baker Cancer Center | Calgary | Alberta |
Canada | Victoria Hospital & Children's Hospital - London Health Sciences Centre | London | Ontario |
Canada | Sunnybrook Health Sciences Centre | Toronto | Ontario |
Canada | Local Institution - 0112 | Vancouver | British Columbia |
China | Beijing Peking Union Medical College Hospital | Beijing | Beijing |
China | Peking University People's Hospital | Beijing | Beijing |
China | The First Hospital of Jilin University | Changchun | Jilin |
China | Xiangya Hospital Central South University | Changsha | Hunan |
China | West China Hospital of Sichuan University | Cheng Du | Sichuan |
China | The First Affiliated Hospital of Chongqing Medical University | Chongqing | Chongqing |
China | Local Institution - 0096 | Fuzhou Fujian | Fujian |
China | Local Institution - 0031 | Guangzhou | Guangdong |
China | The first Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou | Zhejiang |
China | The First Hospital of Harbin | Harbin | Heilongjiang |
China | Anhui Provincial Hospital | Hefei | Anhui |
China | The First Affiliated Hospital of Nanchang University | Nanchang | Jiangxi |
China | Jiangsu Province Hospital | Nanjing | Jiangsu |
China | The Affiliated Hospital of Qingdao University | Qingdao | Shandong |
China | Local Institution - 0218 | Shanghai | Shanghai |
China | The First Hospital of China Medical University | Shenyang | Liaoning |
China | Institute of hematology&blood disease hospital | Tianjin | Tianjin |
China | The First Affiliated Hospital of Wenzhou Medical University | Wenzhou | Zhejiang |
China | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | Hubei |
China | The First Affiliated hospital of Xiamen University | Xiamen | Fujian |
China | Shaanxi provincial people's hospital | Xian | Shaanxi |
China | People's Hospital of Henan Province | Zhengzhou | Henan |
Colombia | Local Institution - 0147 | Medellin | Antioquia |
Colombia | Local Institution - 0149 | Montería | Córdoba |
Colombia | Local Institution - 0152 | Valledupar | Cesar |
Czechia | Local Institution - 0080 | Brno | Brno-mesto |
Czechia | Fakultni nemocnice Ostrava | Ostrava | Moravskoslezský Kraj |
Czechia | Vseobecna fakultni nemocnice v Praze | Praha 2 | |
France | Chu Grenoble Alpes | La Tronche | Isère |
France | Centre Hospitalier Universitaire de Nice - Hôpital l'Archet | Nice | Alpes-Maritimes |
France | Hôpital Saint-Louis | Paris | |
France | CHU Bordeaux Haut-Leveque | Pessac | Aquitaine |
France | Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE | Toulouse | |
France | Local Institution - 0019 | Tours | Indre-et-Loire |
France | Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois | Vandoeuvre lès Nancy | Lorraine |
France | Local Institution - 0248 | Villejuif | Val-de-Marne |
Germany | Local Institution - 0028 | Berlin | |
Germany | Praxis fur Hamatologie und Onkologie | Berlin | |
Germany | Universitaetsklinikum Duesseldorf | Düsseldorf | |
Germany | Local Institution - 0261 | Erding | Bayern |
Germany | Local Institution - 0251 | Jena | Thüringen |
Germany | Local Institution - 0250 | Kempten | Bayern |
Germany | Local Institution - 0168 | Koblenz | Rheinland-Pfalz |
Germany | Universitätsklinikum Leipzig | Leipzig | Sachsen |
Germany | Local Institution - 0255 | Lübeck | |
Germany | Local Institution - 0259 | Münster | Nordrhein-Westfalen |
Germany | Kliniken Ostalb, Stauferklinikum | Mutlangen | |
Germany | Gemeinschaftspraxis Dr. med. Björn Schöttker & Dominik Pretscher | Würzburg | |
Greece | University Hospital of Alexandroupolis | Alexandroupolis | |
Greece | General Hospital of Athens "G. Gennimatas" | Athens | Attikí |
Greece | Attikon General University Hospital | Chaidari | Attikí |
Greece | Local Institution - 0132 | Patras | Acha?a |
Greece | Local Institution - 0242 | Patras | Acha?a |
Hungary | Semmelweis Egyetem | Budapest | |
Hungary | Heves Vármegyei Markhot Ferenc Oktatókórház és Rendelointézet | Eger | Heves |
Hungary | Szabolcs Szatmár Bereg Vármegyei Oktatókórház | Nyiregyhaza | Szabolcs-Szatmár-Bereg |
India | Local Institution - 0243 | Ahmedabad | Gujarat |
India | Local Institution - 0177 | Bengaluru | Karnataka |
India | Local Institution - 0178 | Bhubaneswar | Odisha |
India | Local Institution - 0185 | Hyderabad | |
India | Local Institution - 0186 | New Delhi | |
India | Local Institution - 0193 | New Delhi | Delhi |
India | Local Institution - 0235 | New Delhi | Delhi |
Italy | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola | Bologna | |
Italy | Azienda Ospedaliera Universitaria Careggi | Firenze | Toscana |
Italy | ASST Grande Ospedale Metropolitano Niguarda | Milan | Milano |
Italy | Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico | Milano | Lombardia |
Italy | Local Institution - 0076 | Reggio Calabria | |
Italy | Local Institution - 0244 | Roma | |
Italy | Local Institution - 0256 | Rome | Lazio |
Italy | Humanitas | Rozzano | Milano |
Italy | Azienda Ospedaliera Ordine Mauriziano di Torino | Torino | Piemonte |
Italy | Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma | Verona | |
Mexico | Hematológica Alta Especialidad SC, consultorio 830 | Huixquilucan | |
Mexico | Local Institution - 0142 | Mexico City | Distrito Federal |
Mexico | Unidad Médica Onco-hematológica | Puebla | |
Poland | Uniwersyteckie Centrum Kliniczne | Gdansk | |
Poland | Pratia Onkologia Katowice | Katowice | |
Poland | Specjalistyczny Szpital im. dra Alfreda Sokolowskiego w Walbrzychu | Walbrzych | Dolnoslaskie |
Poland | MTZ Clinical Research powered by Pratia | Warsaw | |
Puerto Rico | Auxilio Mutuo Cancer Center | San Juan | |
Puerto Rico | Local Institution - 0237 | San Juan | |
Spain | Hospital Universitari Vall d'Hebron | Barcelona | Barcelona [Barcelona] |
Spain | Local Institution - 0199 | Granada | |
Spain | Institut Català d'Oncologia - L'Hospitalet | L'Hospitalet de Llobregat | Catalunya [Cataluña] |
Spain | Local Institution - 0252 | Madrid | |
Spain | Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca | Salamanca | |
Spain | Hospital Clinico de Valencia | Valencia | Valenciana, Comunitat |
United States | Our Lady of the Lake RMC | Baton Rouge | Louisiana |
United States | American Oncology Partners of Maryland, PA | Bethesda | Maryland |
United States | Community Cancer Institute | Clovis | California |
United States | The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
United States | John Muir Medical Center - Concord Campus | Concord | California |
United States | Pontchartrain Cancer Center | Covington | Louisiana |
United States | Halifax Health Medical Center | Daytona Beach | Florida |
United States | Local Institution - 0230 | Daytona Beach | Florida |
United States | Local Institution - 0098 | Fort Collins | Colorado |
United States | Florida Cancer Specialists - South | Fort Myers | Florida |
United States | Compassionate Cancer Care Medical Group | Fountain Valley | California |
United States | Local Institution - 0095 | Fresno | California |
United States | John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey |
United States | Hartford Hospital (HH) | Hartford | Connecticut |
United States | Hattiesburg Clinic Hematology/Oncology | Hattiesburg | Mississippi |
United States | Local Institution - 0240 | Honolulu | Hawaii |
United States | University of Texas MD Anderson Cancer Center | Houston | Texas |
United States | Baptist MD Anderson Cancer Center | Jacksonville | Florida |
United States | Kadlec Clinic Hematology and Oncology | Kennewick | Washington |
United States | University of Tennessee Medical Center | Knoxville | Tennessee |
United States | D&H Cancer Research Center LLC | Margate | Florida |
United States | Yale-New Haven Hospital | New Haven | Connecticut |
United States | Local Institution - 0097 | New Orleans | Louisiana |
United States | Local Institution - 0247 | Orange | California |
United States | Ventura County Hematology Oncology Specialists | Oxnard | California |
United States | Local Institution - 0232 | Pikeville | Kentucky |
United States | BRCR Global | Plantation | Florida |
United States | Local Institution - 0236 | Richmond | Virginia |
United States | Blue Ridge Cancer Care | Roanoke | Virginia |
United States | Metro-Minnesota Community Clinical Oncology | Saint Louis Park | Minnesota |
United States | Florida Cancer Specialists - North | Saint Petersburg | Florida |
United States | Local Institution - 0213 | Seattle | Washington |
United States | Orchard Healthcare Research Inc. | Skokie | Illinois |
United States | Local Institution - 0238 | Tamarac | Florida |
United States | Moffitt Cancer Center | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
Bristol-Myers Squibb |
United States, Argentina, Australia, Brazil, Canada, China, Colombia, Czechia, France, Germany, Greece, Hungary, India, Italy, Mexico, Poland, Puerto Rico, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with lower-risk non-transfusion dependent myelodysplastic syndromes (NTD-MDS) who converted to Transfusion Dependence (TD) during any continuous 16-week interval within the 96-week treatment period | TD is defined as = 3 red blood cells (RBC) units/16 weeks assessed by International Working Group (IWG) 2018. | Up to Week 96 | |
Secondary | Number of participants with an increase from baseline in mean Hb values of = 1.5 grams/deciliter (g/dL) in any continuous 16-week interval within the 48 week Treatment Period in the absence of transfusion | Up to Week 48 | ||
Secondary | Number of participants with an increase from baseline in mean Hb values of = 1.5 g/dL in any continuous 24-week interval within the 48-week and 96-week treatment period in the absence of transfusion | Up to Week 48 | ||
Secondary | Number of participants with an increase from baseline in mean Hb values of = 1.5 g/dL in any continuous 24-week interval within the 48-week and 96-week treatment period in the absence of transfusion | From Week 49 to Week 96 | ||
Secondary | Number of participants with an increase from baseline in mean Hb values of = 1.5 g/dL in any continuous 24-week interval within the 48-week and 96-week treatment period in the absence of transfusion | Up to Week 96 | ||
Secondary | Number of participants with an increase from baseline in mean Hb values of = 1.0 g/dL in any continuous 24-week interval within the 48-week and 96-week treatment period in the absence of transfusion | Up to Week 48 | ||
Secondary | Number of participants with an increase from baseline in mean Hb values of = 1.0 g/dL in any continuous 24-week interval within the 48-week and 96-week treatment period in the absence of transfusion | From Week 49 to Week 96 | ||
Secondary | Number of participants with an increase from baseline in mean Hb values of = 1.0 g/dL in any continuous 24-week interval within the 48-week and 96-week treatment period in the absence of transfusion | Up to Week 96 | ||
Secondary | Mean Hb change over fixed 24-week periods compared to the baseline Hb | Baseline, Week 24, Week 48, Week 72, Week 96 | ||
Secondary | Number of participants with an increase from baseline in mean Hb values of = 1.5 g/dL in any continuous 16-week interval within the 96-week treatment period in the absence of transfusion | Up to Week 96 | ||
Secondary | Number of participants with TD by week 48 | Up to Week 48 | ||
Secondary | Time to TD (IWG 2018 defined as = 3 RBC units/16 weeks) during any continuous 16-week interval until the end of study | Up to 5 years | ||
Secondary | Time from first Luspatercept dose to first RBC transfusion | Up to 5 years | ||
Secondary | Duration of median hematologic improvement in erythroid response(mHI-E) in participants with an increase from baseline in mean Hb values of =1.5g/dL in any continuous 16-week interval within 48-week treatment period in absence of transfusion | Up to Week 48 | ||
Secondary | Duration of median hematologic improvement in erythroid response(mHI-E) in participants with an increase from baseline in mean Hb values of =1.5g/dL in any continuous 16-week interval within 96-week treatment period in absence of transfusion | Up to Week 96 | ||
Secondary | Time from first dose to first day of response (increase in mean Hb values of = 1.5 g/dL in any continuous 16-week interval within the 48-week Treatment Period in the absence of transfusion) | Up to Week 48 | ||
Secondary | Time from first dose to first day of response (increase in mean Hb values of = 1.5 g/dL in any continuous 16-week interval within the 96-week Treatment Period in the absence of transfusion) | Up to Week 96 | ||
Secondary | Number of participants with RBC transfusion independence over at least a consecutive 24-week period | Up to 5 years | ||
Secondary | Number of transfusions | Up to 5 years | ||
Secondary | Number of transfusions visits/units | Up to 5 years | ||
Secondary | Change from baseline in subscales of self-reported health-related quality-of-life (HRQoL) assessed by the Functional Assessment of Cancer Therapy - Anemia (FACT-An) | Baseline, Up to 5 years | ||
Secondary | Change from baseline in self-reported HRQoL assessed by the European quality of life questionnaire 5-dimension (EQ-5D-5L) | Baseline, Up to 5 years | ||
Secondary | Number of participants with adverse events (AEs) | Up to Week 102 | ||
Secondary | Number of participants with antidrug antibody (ADA) (positive or negative) | Up to Week 102 | ||
Secondary | Pharmacokinetics (PK): Serum concentration | Up to Week 96 | ||
Secondary | PK: Area under the plasma concentration time curve (AUC) | Up to Week 96 | ||
Secondary | Number of participants with a platelet response at Week 24, Week 48 and Week 96 | Platelet response is defined as an increase from baseline in number of platelets to = 30 × 10^9/L at Week 24, Week 48 and Week 96. | Up to Week 96 | |
Secondary | Number of participants with a neutrophil response at Week 24, Week 48 and Week 96 | Neutrophil response is defined as an absolute increase from baseline of > 0.5 × 10^9/L neutrophils at Week 24, Week 48 and Week 96. | Up to Week 96 | |
Secondary | Number of participants with acute myeloid leukemia (AML) progression | Up to 5 years | ||
Secondary | Time to AML progression | Up to 5 years | ||
Secondary | Number of participants with high risk myelodysplastic syndromes (MDS) progression | Up to 5 years | ||
Secondary | Time to high-risk MDS progression | Up to 5 years | ||
Secondary | Time from date of randomization up to death due to any cause | Up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Terminated |
NCT04313881 -
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
|
Phase 3 | |
Recruiting |
NCT05088356 -
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
|
Phase 1 | |
Recruiting |
NCT04003220 -
Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
|
||
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Active, not recruiting |
NCT03755414 -
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
|
Phase 1 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Terminated |
NCT04866056 -
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
|
Phase 1/Phase 2 | |
Recruiting |
NCT04701229 -
Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes
|
||
Suspended |
NCT04485065 -
Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS
|
Phase 1 | |
Recruiting |
NCT04174547 -
An European Platform for Translational Research in Myelodysplastic Syndromes
|
||
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Completed |
NCT02508870 -
A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
|
Phase 1 | |
Completed |
NCT04543305 -
A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
|
Phase 1 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Recruiting |
NCT05365035 -
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
|
Phase 2 | |
Recruiting |
NCT06008405 -
Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy
|
Phase 1 | |
Not yet recruiting |
NCT05969821 -
Clonal Hematopoiesis of Immunological Significance
|
||
Withdrawn |
NCT05170828 -
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
|
Phase 1 |